EAS-LatAm webinar: Triglyceride-rich lipoproteins as contributors to residual risk

There have long been debates regarding the atherogenic role of triglyceride-rich lipoproteins (TRL) and whether mild or moderate increases should be addressed pharmacologically. While not all the mechanisms explaining the residual risk are known, TRLs are believed to play a significant role. Gaining a better understanding of the effects of TRL on the atherosclerotic process is crucial for enhancing our knowledge of how to manage hypertriglyceridemia.